Search results
Results from the WOW.Com Content Network
A histopathologic diagnosis of prostate cancer is the discernment of whether there is a cancer in the prostate, as well as specifying any subdiagnosis of prostate cancer if possible. The histopathologic subdiagnosis of prostate cancer has implications for the possibility and methodology of any subsequent Gleason scoring . [ 1 ]
A tumor marker is a biomarker that can be used to indicate the presence of cancer or the behavior ... lymphoma, leukemia, lung cancer, prostate cancer [17 ...
Prostate cancer antigen 3 (PCA3, also referred to as DD3) is a gene that expresses a non-coding RNA. PCA3 is only expressed in human prostate tissue, and the gene is highly overexpressed in prostate cancer. [3] [4] Because of its restricted expression profile, the PCA3 RNA is useful as a tumor marker. [5]
This tumor marker can be detected in the blood, saliva, or urine. [17] The possibility of identifying an effective biomarker for early cancer diagnosis has recently been questioned, in light of the high molecular heterogeneity of tumors observed by next-generation sequencing studies. [23]
Biomarkers found in blood, urine, or body tissues that can be introduced or elevated by the presence of one or more types of cancer. Pages in category "Tumor markers" The following 45 pages are in this category, out of 45 total.
Men without prostate cancer typically have PSA levels of under 4 nanograms per milliliter (ng/mL), according to the American Cancer Society. PSA levels between 4 and 10 suggest you could have ...
It appears to provide more accuracy in identifying early prostate cancer than the standard prostate cancer marker, PSA. "EPCA-2" is not the name of a gene. EPCA-2 gets its name because it is the second prostate cancer marker identified by the research team. This earlier marker was previously known as "EPCA", [1] [2] but is now called "EPCA-1".
Wu et al. (1994) reproduced the human-derived LNCaP tumors in immunocompromised mice by co-injection of LNCaP cells with MS human bone fibroblasts. [6] Cells were subcutaneously injected at multiple sites into the mouse flank and after approximately 4 weeks of growth, tumors were easily detectable by physical examination and had a high rate of growth (17-33 mm3/day).